FY2026 Earnings Forecast for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Issued By Zacks Research

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research cut their FY2026 EPS estimates for Ironwood Pharmaceuticals in a note issued to investors on Tuesday, September 10th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $0.48 per share for the year, down from their prior estimate of $0.71. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.28 per share.

A number of other brokerages have also commented on IRWD. Craig Hallum cut their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a research note on Monday. They set a “market perform” rating and a $5.00 price objective on the stock. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday. Wells Fargo & Company cut their target price on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Finally, StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.57.

Ironwood Pharmaceuticals Trading Up 4.1 %

Shares of IRWD opened at $4.53 on Thursday. The firm has a market capitalization of $709.08 million, a P/E ratio of -0.67 and a beta of 0.49. The stock’s fifty day simple moving average is $5.58 and its 200 day simple moving average is $6.96. Ironwood Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $15.70.

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the transaction, the insider now owns 284,661 shares in the company, valued at approximately $1,215,502.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its stake in Ironwood Pharmaceuticals by 4.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,288,653 shares of the biotechnology company’s stock valued at $14,742,000 after purchasing an additional 57,859 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Ironwood Pharmaceuticals by 35.0% during the 4th quarter. BNP Paribas Financial Markets now owns 572,947 shares of the biotechnology company’s stock worth $6,555,000 after acquiring an additional 148,402 shares in the last quarter. Jump Financial LLC bought a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth $389,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Ironwood Pharmaceuticals in the 4th quarter worth $1,129,000. Finally, Quadrant Capital Group LLC raised its position in shares of Ironwood Pharmaceuticals by 68.8% during the fourth quarter. Quadrant Capital Group LLC now owns 8,578 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 3,497 shares during the period.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.